MARKET

BLPH

BLPH

Bellerophon
NASDAQ

Real-time Quotes | Nasdaq Last Sale

0.3850
+0.0205
+5.62%
Opening 14:15 11/22 EST
OPEN
0.3625
PREV CLOSE
0.3645
HIGH
0.3899
LOW
0.3500
VOLUME
136.49K
TURNOVER
--
52 WEEK HIGH
1.220
52 WEEK LOW
0.3120
MARKET CAP
26.53M
P/E (TTM)
-2.5497
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of BLPH and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 2 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

BLPH News

  • Bellerophon Announces Initial Data From Acute Hemodynamic Dose Escalation Study Of Inopulse For Treatment Of Pulmonary Hypertension Associated With Interstitial Lung Disease; Results 'clinically meaningful improvements' In Pre-Specified Parameters
  • Benzinga.11/12 13:38
  • Bellerophon Announces Positive Initial Data from Acute Hemodynamic Dose Escalation Study of INOpulse® for Treatment of Pulmonary Hypertension Associated with Interstitial Lung Disease
  • GlobeNewswire.11/12 13:30
  • Bellerophon Presents New Data from Cohort 1 of Ongoing Phase 2/3 Study of INOpulse® for Treatment of Pulmonary Hypertension Associated with Interstitial Lung Disease at Pulmonary Fibrosis Foundation Summit 2019
  • GlobeNewswire.11/07 13:30
  • Bellerophon Therapeutics EPS beats by $0.01
  • seekingalpha.11/06 18:38

More

Industry

Biotechnology & Medical Research
+1.65%
Pharmaceuticals & Medical Research
+0.78%

Hot Stocks

Name
Price
%Change

About BLPH

Bellerophon Therapeutics, Inc. is a clinical-stage therapeutics company. The Company is focused on developing products at the intersection of drugs and devices that address medical needs in the treatment of cardiopulmonary diseases. The Company is focused on the development of its nitric oxide therapy for patients with pulmonary hypertension (PH), using its delivery system, INOpulse, with pulmonary arterial hypertension (PAH) as the lead indication. Its INOpulse device has a mechanism that delivers brief, targeted pulses of nitric oxide timed to occur at the beginning of a breath for delivery to the alveoli of the lungs, which minimizes the amount of drug required for treatment. The Company's second program, BCM, is a medical device focused to prevent congestive heart failure following a ST Segment Elevation Myocardial Infarction (STEMI), which is a type of severe heart attack. The Company's BCM is in PRESERVATION I clinical trial.
More

Webull offers Bellerophon Therapeutics Inc (BLPH) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.